SANUWAVE HealthSNWV +4.39%38 EBITDA Margin % is -6.04% as of Mar. 2026. GuruFocus rates SNWV with a GF Score™ of 38/100 and a GF Value™ of $11.86 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 816 Medical Devices & Instruments companies, SANUWAVE Health ranks better than 98.28% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. SANUWAVE Health's EBITDA for the
three
months ended in Mar. 2026 was $-0.58 Mil. SANUWAVE Health's Revenue for the
three
months ended in Mar. 2026 was $9.62 Mil. Therefore, SANUWAVE Health's EBITDA margin for the quarter that ended in Mar. 2026 was -6.04%.
SANUWAVE Health (NAS:SNWV) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
SANUWAVE Health EBITDA Margin % Related Terms
SANUWAVE Health EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for SANUWAVE Health's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SNWV vs QTRX, CVRX, NNOX: EBITDA Margin % Comparison
For the Medical Devices subindustry, SANUWAVE Health's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SANUWAVE Health EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, SANUWAVE Health's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where SANUWAVE Health's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SANUWAVE Health (SNWV) has a EBITDA Margin % of -6.04% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on SANUWAVE Health and its competitors. According to the industry distribution chart, SANUWAVE Health ranks #14 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 1.7%.
Is SANUWAVE Health's EBITDA Margin % too high?
SANUWAVE Health's current EBITDA Margin % is -6.04%. Based on the distribution chart, SANUWAVE Health ranks #14 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, SANUWAVE Health has a GF Score™ of 38/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does SANUWAVE Health's EBITDA Margin % compare to QTRX and CVRX?
According to the Medical Devices & Instruments industry distribution chart, SANUWAVE Health ranks #14 out of 816 companies for EBITDA Margin %. This places SANUWAVE Health in the top 2% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on SANUWAVE Health and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SANUWAVE Health's current EBITDA Margin % is -6.04%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SANUWAVE Health stock overvalued right now?
Based on GuruFocus' analysis, SANUWAVE Health (SNWV) is currently considered Modestly Undervalued. The stock's GF Value™ is $11.86, compared to a current price of $8.57 — trading 27.7% below its estimated fair value. The current EBITDA Margin % is -6.04%. SANUWAVE Health's overall GF Score™ is 38/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For SANUWAVE Health (SNWV), the current EBITDA Margin % is -6.04% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SANUWAVE Health (SNWV) Overvalued in 2026?
Based on GuruFocus' analysis, SANUWAVE Health stock appears to be undervalued.
The current stock price of $8.57 is trading 27.7% below its estimated GF Value™ of $11.86.
GuruFocus considers SANUWAVE Health to be Modestly Undervalued.
Key valuation signals for SNWV:
EBITDA Margin %: -6.04%
GF Value™: $11.86 vs. price of $8.57 (27.7% below fair value)
No single metric tells the full story. See the SNWV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SANUWAVE Health Inc is a medical device company providing directed energy products into the wound care space. It is focused on the commercialization of its patented regenerative medicine utilizing noninvasive ultrasound or shockwaves to produce a biological response promoting the repair and regeneration of tissue, musculoskeletal, and vascular structures. Sanuwave's patented, FDA-cleared, and commercialised product is the UltraMIST system, which is used to treat a variety of acute and chronic wounds using ultrasound technology. The company operates in one reportable segment, the design and sale of medical devices. Geographically, the company generates revenue mainly from the United States.
38GF Score
Get the complete analysis for SNWV
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNWV has been successfully added to your 
